CN107335130A - Portal vein self-retaining formula radioactive particle sleeve pipe and preparation method thereof - Google Patents
Portal vein self-retaining formula radioactive particle sleeve pipe and preparation method thereof Download PDFInfo
- Publication number
- CN107335130A CN107335130A CN201611226048.XA CN201611226048A CN107335130A CN 107335130 A CN107335130 A CN 107335130A CN 201611226048 A CN201611226048 A CN 201611226048A CN 107335130 A CN107335130 A CN 107335130A
- Authority
- CN
- China
- Prior art keywords
- sleeve pipe
- stereo
- portal vein
- radioactive particle
- self
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000003240 portal vein Anatomy 0.000 title claims abstract description 98
- 239000002245 particle Substances 0.000 title claims abstract description 69
- 230000002285 radioactive effect Effects 0.000 title claims abstract description 46
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- 229940044173 iodine-125 Drugs 0.000 claims description 11
- 210000004534 cecum Anatomy 0.000 claims description 3
- 238000007789 sealing Methods 0.000 claims description 3
- ZCYVEMRRCGMTRW-YPZZEJLDSA-N iodine-125 Chemical compound [125I] ZCYVEMRRCGMTRW-YPZZEJLDSA-N 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 abstract description 26
- 201000011510 cancer Diseases 0.000 abstract description 21
- 208000005189 Embolism Diseases 0.000 abstract description 19
- 238000011282 treatment Methods 0.000 abstract description 19
- 230000009286 beneficial effect Effects 0.000 abstract description 9
- 230000008901 benefit Effects 0.000 abstract description 9
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 14
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 14
- PNDPGZBMCMUPRI-XXSWNUTMSA-N [125I][125I] Chemical compound [125I][125I] PNDPGZBMCMUPRI-XXSWNUTMSA-N 0.000 description 13
- 210000004185 liver Anatomy 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 6
- 229910052719 titanium Inorganic materials 0.000 description 6
- 239000010936 titanium Substances 0.000 description 6
- 238000000034 method Methods 0.000 description 5
- 210000004204 blood vessel Anatomy 0.000 description 4
- 238000002513 implantation Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 2
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 2
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 2
- 235000011613 Pinus brutia Nutrition 0.000 description 2
- 241000018646 Pinus brutia Species 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 229960003787 sorafenib Drugs 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010019695 Hepatic neoplasm Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010040007 Sense of oppression Diseases 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 238000002725 brachytherapy Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000010102 embolization Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 210000001758 mesenteric vein Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000000955 splenic vein Anatomy 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
- A61N5/1002—Intraluminal radiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
- A61N5/1007—Arrangements or means for the introduction of sources into the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
- A61N5/1014—Intracavitary radiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N2005/1092—Details
- A61N2005/1096—Elements inserted into the radiation path placed on the patient, e.g. bags, bolus, compensators
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Radiation-Therapy Devices (AREA)
Abstract
The invention discloses a kind of portal vein self-retaining formula radioactive particle sleeve pipe and preparation method, including 3 D stereo sleeve pipe and the radioactive particle in 3 D stereo sleeve pipe, 3 D stereo sleeve pipe is helical structure, be in line type after the tension of 3 D stereo sleeve pipe, after loosening can resilience, 3 D stereo sleeve pipe it is closed at both ends.Its advantage is：Shape in line after 3 D stereo sleeve pipe tenses, just reverts to 3 D stereo shape after loosening.It can so be oppressed using its own elasticity in portal vein inwall, play a part of self-retaining in portal vein, 3 D stereo sleeve pipe optimal morphology should be sped structure.Stereo spiral formula structure is designed as, can not only play a part of voluntarily being fixed in portal vein, screw type particle distribution mode is yet forms both, is more beneficial for the treatment to cancer embolus.
Description
Technical field
The present invention relates to technical field of medical instruments, more particularly to portal vein self-retaining formula radioactive particle sleeve pipe and its system
Preparation Method.
Background technology
The incidence of disease of the hepatocellular carcinoma (HCC) in China is high, accounts for the half of all new cases in the whole world, wherein 10-
40%HCC patient is associated with TTPV.Once main portal vein is involved by cancer embolus, it can be significantly greatly increased in tumour liver and send out generally
Rate, while hinder enter liver portal venous flow and cause hepatic functional reserve to deteriorate and aggravate secondary to the door on liver cirrhosis basis
Venous hypertension, therefore this kind of patient's poor prognosis.Merging main portal vein cancer embolus (MPVTT) currently for HCC there is no standard to control
Treatment scheme.It is considered as the radical treatment method that HCC merges TTPV that liver inner disease foci excision joint portal vein, which takes bolt, but only
There is the idicatio that 10% or so patient meets surgical operation when medical.Research is suffered from it has proven convenient that merging portal vein tumor thrombus for HCC
It is safe, feasible that person implements Arterial chemotherapy and embolization (TACE)；HCC merge MPVTT patient receive TACE, Sorafenib list medicine and
After TACE joint Sorafenib treatments, its median survival interval is respectively 4.1,3.0 and 3.0~7.0 months, and three kinds of therapeutic modalities are equal
MPVTT patient, which may be merged, to HCC brings existence to benefit.
Probability is sent out in HCC livers, hinders enter liver portal venous flow and increase portal venous pressure in view of MPVTT can increase, if
Main portal vein is opened in time using support, is effectively suppressed portal vein tumor thrombus progress using I125 radioactive particle, perhaps can be entered
One step extends the life cycle that HCC merges MPVTT patient.Therefore, Zhongshan Hospital Attached to Fudan Univ takes the lead in having carried out " blood vessel interplantation
Enter I-125 seeds bar and support joint TACE treatments HCC merges MPVTT " clinical research.Preliminary result shows：Implantation branch
The patency of portal vein trunk can be restored in time after frame, and continuation low dose radiation can suppress cancer caused by I-125 seeds bar
The progress of bolt.In I-125 seeds bar combined bracket treats MPVTT, support, which plays, recovers the effect of main portal vein blood flow, and
Particle bar then plays a part for the treatment of cancer embolus.However, Stent Implantation and particle bar simultaneously in portal vein, technology is relative complex,
Puncture channel substantially makes bleeding risk higher and costly, therefore the country is not carried out extensively.
After support opens main portal vein, portal venous flow is recovered, and this not only mean onlys that normal liver can obtain
More blood supplies, it is often more important that for the creation chance of the TACE treatments of tumour in liver.This is that above-mentioned " blood vessel is implanted into iodine-125 grain
Sub- bar and support joint TACE treatments HCC merges MPVTT " clinical researches most important theories basis.HCC patient TACE is treated relative
Contraindication is that main portal vein entirely shuts, but with the maturation for widely using and intervening Doctors' skill of microtubular, precisely and
The TACE treatments of appropriateness are feasible.And in most cases, main portal vein not entirely shuts or has that side shoot is compensatory,
It is safe and feasible to carry out Superselective catheterization row TACE treatments, and this has been recognized.Therefore, since merging MPVTT for most of
HCC can row TACE treatment, then portal vein support insert and it is nonessential.On the other hand, join in I-125 seeds bar
Close in stent in the treatment MPVTT, because line style particle bar (particle bar is line style at present) can not be fixed in portal vein, therefore support
Another effect played is then that the compressing of particle bar is fixed on into portal vein inwall, so that particle bar plays low coverage in cancer embolus region
Acted on from radiotherapy.It is fixed on using the contention effect of support in portal vein, plays brachytherapy effect.However, particle bar quilt
Support pressure is under the pressure of cancer embolus side or the normal side wall of portal vein, then uncontrollable.The portal vein stent diameter inserted is often 14mm, and
The a diameter of 17mm of Net long wave radiation of particle bar, if particle bar is located at the normal side wall of portal vein of cancer embolus offside, grain can be influenceed
Therapeutic action of the sub- bar to cancer embolus.
Try to can voluntarily be fixed on particle bar in the portal vein in cancer embolus region, then without Stent Implantation to oppress
Fixed particle bar.So, when treating such lesion without portal vein support, then it can substantially reduce intervention operating difficulty, reduce out
Blood risk and surgery cost, thus may be such that this therapeutic modality is carried out extensively, allow more patients to be benefited.Meanwhile
Screw type particle distribution mode, is more beneficial for the treatment to cancer embolus.
The content of the invention
For the one or more to solve the above problems, there is provided portal vein self-retaining formula radioactive particle sleeve pipe and its preparation side
Method.
According to an aspect of the present invention, there is provided a kind of portal vein self-retaining formula radioactive particle sleeve pipe, including it is three-dimensional vertical
Body sleeve pipe and the radioactive particle in 3 D stereo sleeve pipe, 3 D stereo sleeve pipe are helical structure, 3 D stereo sleeve pipe
Be in line type after tension, after loosening can resilience, 3 D stereo sleeve pipe it is closed at both ends.Its advantage is：3 D stereo set
Shape in line after pipe tenses, just reverts to 3 D stereo shape after loosening.It can so be oppressed using its own elasticity quiet in door
Arteries and veins inwall, play a part of self-retaining in portal vein, 3 D stereo sleeve pipe optimal morphology should be sped structure.It is designed as standing
Body sped structure, it can not only play a part of voluntarily being fixed in portal vein, yet forms both screw type particle distribution side
Formula, it is more beneficial for the treatment to cancer embolus.
In some embodiments, 3 D stereo sleeve pipe is helical structure.Its advantage is：3 D stereo sleeve pipe is optimal
Form should be sped structure.Stereo spiral formula structure is designed as, can not only play a part of voluntarily being fixed in portal vein,
Screw type particle distribution mode is yet forms both, is more beneficial for the treatment to cancer embolus.
In some embodiments, radioactive particle is iodine-125 radioactive particle.
In some embodiments, iodine-125 radioactive particle includes titanium shell and the silver in titanium shell
Rod, silver-colored rod adsorption have iodine-125 radionuclide.
In some embodiments, the width of 3 D stereo sleeve pipe is more than main portal vein diameter.Its advantage is：Should
The width of 3 D stereo sleeve pipe should be big compared with main portal vein diameter, can so be oppressed using its own elasticity in portal vein
Wall, play a part of self-retaining in portal vein.
In some embodiments, the width of 3 D stereo sleeve pipe is bigger than main portal vein diameter by 10~20%.Its is beneficial
Effect is：The width of the 3 D stereo sleeve pipe should be big compared with main portal vein diameter by 10~20%, can so utilize its own bullet
Sexual oppression plays a part of self-retaining in portal vein in portal vein inwall.
According to another aspect of the present invention, the preparation method of portal vein self-retaining formula radioactive particle sleeve pipe, its feature
It is, comprises the following steps,
Prepare 3 D stereo sleeve pipe, 3 D stereo sleeve pipe is helical structure, and be in line type after the tension of 3 D stereo sleeve pipe, puts
After pine can resilience, the first port of 3 D stereo sleeve pipe is cecum；Will at the second port of 3 D stereo sleeve pipe with seal wire
More pieces of radioactive particle sources are pushed in pipe, and the second port of 3 D stereo sleeve pipe is carried out into heat sealing.Its advantage is：This
The portal vein self-retaining formula radioactive particle sleeve pipe that kind method prepares has relatively stable structure, and preparation method letter
It is single, it is easy to operate.Wherein 3 D stereo sleeve pipe optimal morphology should be sped structure, be designed as stereo spiral formula structure, not only
It can play a part of voluntarily being fixed in portal vein, yet forms both screw type particle distribution mode, be more beneficial for cancer embolus
Treatment.
In some embodiments, radioactive particle is iodine-125 radioactive particle.
In some embodiments, the width of 3 D stereo sleeve pipe is more than main portal vein diameter.Its advantage is：Should
The width of 3 D stereo shape sleeve pipe should be big compared with main portal vein diameter, can so be oppressed using its own elasticity in portal vein
Wall, play a part of self-retaining in portal vein.
In some embodiments, the width of 3 D stereo sleeve pipe is more than main portal vein diameter.Its advantage is：Should
The width of 3 D stereo sleeve pipe should be big compared with main portal vein diameter by 10~20%, can so be oppressed using its own elasticity in door
Vein inwall, play a part of self-retaining in portal vein.
Brief description of the drawings
Fig. 1 is the portal vein self-retaining formula radioactive particle sleeve structure schematic diagram of an embodiment of the present invention；
Fig. 2 is the radioactive particle structural representation of the radioactive particle sleeve pipe of portal vein self-retaining formula shown in Fig. 1；
Fig. 3 is the use state figure of portal vein self-retaining formula radioactive particle sleeve pipe of the present invention.
3 D stereo sleeve pipe 1, first port 101, second port 102, radioactive particle source 2, titanium shell 201, silver-colored rod
202, liver 3, tumour 4, right branch of portal vein 5, left branch of portal vein 6, main portal vein 7, splenic vein 8, superior mesenteric vein 9, cancer
Bolt 10.
Embodiment
The invention will now be described in further detail with reference to the accompanying drawings.
Referring to Figures 1 and 2, a kind of portal vein self-retaining formula radioactive particle sleeve pipe, including 3 D stereo sleeve pipe 1 and set
In the radioactive particle 2 in 3 D stereo sleeve pipe 1,3 D stereo sleeve pipe 1 is helical structure, 3 D stereo sleeve pipe 1 tense after into
Linear pattern, after loosening can resilience, 3 D stereo sleeve pipe 1 it is closed at both ends.Preferably, radioactive particle 2 radiates for iodine-125
Property particle.Wherein iodine-125 radioactive particle existing can be used clinically, specifically can include titanium shell 201 and
Silver-colored rod 202 in titanium shell 201, the silver-colored adsorption of rod 202 have iodine-125 radionuclide.The length of titanium shell 201
Spend for 4.5mm, a diameter of 0.8mm.The length of silver-colored rod 202 is 3~4mm.Shape in line after 3 D stereo sleeve pipe 1 tenses, puts
Just 3 D stereo shape is reverted to after pine.3 D stereo sleeve pipe 1 can apply the common conduit conduct commonly used in blood vessel intervention operation
The material of 3 D stereo sleeve pipe 1, a diameter of 4F.It can so be oppressed in portal vein inwall, be played from solid using its own elasticity
Due to the effect in portal vein, the optimal morphology of 3 D stereo sleeve pipe 1 should be sped structure.Stereo spiral formula structure is designed as,
It can not only play a part of voluntarily being fixed in portal vein, yet forms both screw type particle distribution mode, be more beneficial for pair
The treatment of cancer embolus 10.
Preferably, the width of 3 D stereo sleeve pipe 1 is more than the diameter of main portal vein 7.More preferably, the width of three-dimensional sleeve pipe 1 is tieed up
Degree is bigger by 10%~20% than the diameter of main portal vein 7.The width of the 3 D stereo sleeve pipe 1 should be big compared with the diameter of main portal vein 7
10%~20% or so, it can so be oppressed using its own elasticity in portal vein inwall, play self-retaining in portal vein
Effect.The length of 3 D stereo sleeve pipe 1 can be according to cancer embolus 10 depending on the length that portal vein is accumulated.
According to another aspect of the present invention, there is provided a kind of preparation side of portal vein self-retaining formula radioactive particle sleeve pipe
Method, comprise the following steps, prepare 3 D stereo sleeve pipe 1,3 D stereo sleeve pipe 1 is helical structure, after 3 D stereo sleeve pipe 1 tenses
Be in line type, being capable of resilience after loosening；It is cecum by the first port 101 of 3 D stereo sleeve pipe 1；With seal wire from 3 D stereo set
More pieces of radioactive particles 2 are pushed in pipe at the second port 102 of pipe 1, the second port 102 of 3 D stereo sleeve pipe 1 is entered
Row heat sealing.Wherein, 3 D stereo sleeve pipe 1 can apply the common conduit commonly used in blood vessel intervention operation as 3 D stereo set
The material of pipe 1, a diameter of 4F.Its advantage is：The portal vein self-retaining formula radioactive particle set that this method prepares
Pipe has relatively stable structure, and preparation method is simple, easy to operate.The wherein optimal morphology of 3 D stereo sleeve pipe 1 should be
Sped structure, is designed as stereo spiral formula structure, can not only play a part of voluntarily being fixed in portal vein, yet forms both
Screw type particle distribution mode, is more beneficial for the treatment to cancer embolus 10.
Wherein, radioactive particle 2 is iodine-125 radioactive particle.
Preferably, the width of 3 D stereo sleeve pipe 1 is more than the diameter of main portal vein 7.More preferably, the width of three-dimensional sleeve pipe 1 is tieed up
Degree is bigger by 10%~20% than the diameter of main portal vein 7.The width of the 3 D stereo sleeve pipe 1 should be big compared with the diameter of main portal vein 7
10%~20% or so, it can so be oppressed using its own elasticity in portal vein inwall, play self-retaining in portal vein
Effect.
During using portal vein self-retaining formula radioactive particle sleeve pipe of the invention, as shown in figure 3, tumour 4 is located at portal vein
At right branch 5, cancer embolus 10 invades right branch of portal vein 5 and main portal vein 7, percutaneously punctures branch of portal vein through liver 3, introduce 4F or
In the long sheaths of 5F to main portal vein 7, head end exceedes the lower edge of cancer embolus 10, then by the portal vein self-retaining formula radioactivity of the present invention
After particle sleeve pipe stretches, the leading portion of sheath is pushed to through long sheath, behind the position for determining storing, seal wire fixes the radioactivity of the present invention
Particle sleeve pipe simultaneously withdraws long sheath, and now particle bar is just progressively discharged to portal vein, and is progressively deployed with 3 D stereo shape structure,
Oppressed by its elasticity in portal vein inwall, play a part of self-retaining in portal vein, while screw type particle distribution side
Formula, it is more beneficial for the treatment to cancer embolus 10.
Above-described is only some embodiments of the present invention.For the person of ordinary skill of the art, not
On the premise of departing from the invention design, various modifications and improvements can be made, these belong to the protection model of the present invention
Enclose.
Claims (9)
1. portal vein self-retaining formula radioactive particle sleeve pipe, it is characterised in that including 3 D stereo sleeve pipe (1) and located at described
Radioactive particle (2) in 3 D stereo sleeve pipe (1), be in line type after 3 D stereo sleeve pipe (1) tension, can after loosening
Resilience, the 3 D stereo sleeve pipe (1) it is closed at both ends.
2. portal vein self-retaining formula radioactive particle sleeve pipe according to claim 1, it is characterised in that the 3 D stereo
Sleeve pipe (1) is helical structure.
3. portal vein self-retaining formula radioactive particle sleeve pipe according to claim 1, it is characterised in that the radioactivity grain
Sub (2) are iodine-125 radioactive particle.
4. portal vein self-retaining formula radioactive particle sleeve pipe according to claim 1, it is characterised in that the 3 D stereo
The width of sleeve pipe (1) is more than the main portal vein (7) diameter.
5. portal vein self-retaining formula radioactive particle sleeve pipe according to claim 1, it is characterised in that the 3 D stereo
The width of sleeve pipe (1) is bigger by 10~20% than the main portal vein (7) diameter.
6. the preparation method of portal vein self-retaining formula radioactive particle sleeve pipe, it is characterised in that comprise the following steps,
Prepare 3 D stereo sleeve pipe (1), the 3 D stereo sleeve pipe (1) is helical structure, and the 3 D stereo sleeve pipe (1) tenses
After be in line type, after loosening can resilience, the first port (101) of the 3 D stereo sleeve pipe (1) is cecum；
More pieces of radioactive particles (2) are pushed into pipe from the second port (102) of the 3 D stereo sleeve pipe (1) with seal wire
It is interior；
The second port (102) of the 3 D stereo sleeve pipe (1) is subjected to heat sealing.
7. a kind of preparation method of portal vein self-retaining formula radioactive particle sleeve pipe according to claim 6, its feature exist
In the radioactive particle (2) is iodine-125 radioactive particle.
8. a kind of preparation method of portal vein self-retaining formula radioactive particle sleeve pipe according to claim 6, its feature exist
In the width of the 3 D stereo sleeve pipe (1) is more than the main portal vein (7) diameter.
9. a kind of preparation method of portal vein self-retaining formula radioactive particle sleeve pipe according to claim 6, its feature exist
In the width of the 3 D stereo sleeve pipe (1) is more than the 10~20% of the main portal vein (7) diameter.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611226048.XA CN107335130A (en) | 2016-12-27 | 2016-12-27 | Portal vein self-retaining formula radioactive particle sleeve pipe and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611226048.XA CN107335130A (en) | 2016-12-27 | 2016-12-27 | Portal vein self-retaining formula radioactive particle sleeve pipe and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107335130A true CN107335130A (en) | 2017-11-10 |
Family
ID=60222033
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611226048.XA Pending CN107335130A (en) | 2016-12-27 | 2016-12-27 | Portal vein self-retaining formula radioactive particle sleeve pipe and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107335130A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109847202A (en) * | 2019-04-08 | 2019-06-07 | 郑州大学第一附属医院 | Portal vein seed stent implantation system |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102596174A (en) * | 2009-09-10 | 2012-07-18 | 塔里斯生物医药公司 | Implantable device for controlled drug delivery |
| CN203539496U (en) * | 2013-11-01 | 2014-04-16 | 巴格那 | Medical support |
| CN203790087U (en) * | 2014-01-09 | 2014-08-27 | 刘阳 | Radioactive particle stent |
| US20140378739A1 (en) * | 2013-06-20 | 2014-12-25 | Source Production & Equipment Co., Inc. | Radioactive therapeutic device with fixation |
| CN204275281U (en) * | 2014-09-29 | 2015-04-22 | 潘阳林 | A kind of biliary tract chemotherapy support |
| CN204798622U (en) * | 2015-06-23 | 2015-11-25 | 颜标 | Novel medical treatment is dissolved and is tied vascular pipe |
| CN105920727A (en) * | 2016-04-11 | 2016-09-07 | 王娟 | Radioactive particle chain and use method thereof |
| CN206745740U (en) * | 2016-12-27 | 2017-12-15 | 王万胜 | Portal vein self-retaining formula radioactive particle sleeve pipe |
-
2016
- 2016-12-27 CN CN201611226048.XA patent/CN107335130A/en active Pending
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102596174A (en) * | 2009-09-10 | 2012-07-18 | 塔里斯生物医药公司 | Implantable device for controlled drug delivery |
| US20140378739A1 (en) * | 2013-06-20 | 2014-12-25 | Source Production & Equipment Co., Inc. | Radioactive therapeutic device with fixation |
| CN203539496U (en) * | 2013-11-01 | 2014-04-16 | 巴格那 | Medical support |
| CN203790087U (en) * | 2014-01-09 | 2014-08-27 | 刘阳 | Radioactive particle stent |
| CN204275281U (en) * | 2014-09-29 | 2015-04-22 | 潘阳林 | A kind of biliary tract chemotherapy support |
| CN204798622U (en) * | 2015-06-23 | 2015-11-25 | 颜标 | Novel medical treatment is dissolved and is tied vascular pipe |
| CN105920727A (en) * | 2016-04-11 | 2016-09-07 | 王娟 | Radioactive particle chain and use method thereof |
| CN206745740U (en) * | 2016-12-27 | 2017-12-15 | 王万胜 | Portal vein self-retaining formula radioactive particle sleeve pipe |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109847202A (en) * | 2019-04-08 | 2019-06-07 | 郑州大学第一附属医院 | Portal vein seed stent implantation system |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8080057B2 (en) | Methods and devices for breast reconstruction | |
| CN104436417B (en) | One kind is used for perfusion thrombolysis catheter in human vas | |
| EP2070493A1 (en) | Duct stent being capable of carrying the subminiature radioactive particle source | |
| CN103877675A (en) | Intracavity radioactive-particle implant | |
| Yoon et al. | Clinical benefit of hepatic arterial infusion concurrent chemoradiotherapy in locally advanced hepatocellular carcinoma: a propensity score matching analysis | |
| CN206745740U (en) | Portal vein self-retaining formula radioactive particle sleeve pipe | |
| JP2019528943A (en) | Apparatus and method for vascular hyperperfusion in extravascular space | |
| CN204745343U (en) | Biliary tract drainage device that can nimble load active particles | |
| CN107335130A (en) | Portal vein self-retaining formula radioactive particle sleeve pipe and preparation method thereof | |
| Shaitelman et al. | American Brachytherapy Society Task Group Report: long-term control and toxicity with brachytherapy for localized breast cancer | |
| Lee et al. | Intravascular fasciitis of the common femoral vein | |
| CN204840652U (en) | Ureter radiotherapy associated drainage catheter | |
| CN218793363U (en) | IV port | |
| CN200960355Y (en) | A pipeline support capable of carrying miniature radioactive particle sources | |
| CN110755758A (en) | Drainage tube capable of carrying radioactive particles | |
| CN111449722A (en) | An intravascular delivery system | |
| CN104042374B (en) | Abdominal dropsy internal-drainage one-way support | |
| Yuan et al. | Treatment of obstructive jaundice induced by non-hodgkin lymphoma with EUS-guided transgastric anterograde common bile duct stenting: Technical case report and literature review | |
| CN201006055Y (en) | Biliary support internal and external drainage and continuous intracavitary brachytherapy combination kit | |
| CN105749415A (en) | Balloon catheter applied to portal vein | |
| CN209564510U (en) | It is a kind of to combine the venous transfusion port for applying source device | |
| CN205913430U (en) | Tectorial membrane support conveyer | |
| Ji et al. | Minimally invasive intervention of obstructive jaundice in pancreatic cancer | |
| CN208741206U (en) | A kind of transportation system of vena cava filter | |
| CN223682841U (en) | A type of internal and external biliary drainage device |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20171110 |